Investors

Homology Medicines is focused on advancing our genetic medicines platform as one-time treatments and potential cures for patients with rare diseases

Homology Medicines is focused on advancing our genetic medicines platform as one-time treatments and potential cures for patients with rare diseases

Analyst Coverage

Firm Analyst
Baird
 Jack Allen
BofA Securities
Jason Zemansky
Chardan
 Matthew Barcus, Ph.D.
Credit Suisse Securities
 Richard Law
H.C. Wainwright & Co.
Patrick R. Trucchio, CFA
Oppenheimer
 Matthew Biegler
RBC Capital Markets, LLC
 Luca Issi, Ph.D.
Stifel
 Dae Gon Ha, Ph.D.
TD Cowen
 Phil Nadeau, Ph.D.

Homology Medicines, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Homology Medicines, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Homology Medicines, Inc. or its management. Homology Medicines, Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.